

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Pinaverium 100 mg Tablet (DIN 02469685) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2020**.

PINAVERIUM BROMIDE

100 MG TABLET

00002469685	APO-PINAVERIUM	APX	\$ 0.5346
00002230684	DICETEL	BGP	\$ 0.6419

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage for Desmopressin 10 mcg/dose Nasal Spray (DIN 02242465) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 3, 2020**.

DESMOPRESSIN ACETATE

10 MCG / DOSE NASAL METERED DOSE SPRAY

00002242465	DESMOPRESSIN	AAP	\$ 1.5222
00000836362	DDAVP	FEI	\$ 1.9796

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Phenytoin 25 mg/ml Oral Suspension (DIN 02250896) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 6, 2020**.

PHENYTOIN

25 MG / ML ORAL SUSPENSION

00002250896	TARO-PHENYTOIN	TAR	\$ 0.0428
00000023450	DILANTIN-125	PFI	\$ 0.0571

... continued from previous page

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Benzoyl Peroxide/Clinda Kit 5%/1% Topical Gel (DIN 02464519) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 8, 2020**.

CLINDAMYCIN PHOSPHATE/ BENZOYL PEROXIDE

1 % / 5 % TOPICAL GEL

00002464519	TARO-BENZOYL PEROXIDE/CLINDAMYCIN KIT	TAR	\$ 0.7422
00002248472	BENZACLIN	VCL	\$ 1.0141

Alberta Blue Cross has been advised by Auro Pharma Inc., Sandoz Canada Inc., Sanis Health Inc, Sivem Pharmaceuticals ULC and Teva Canada Limited that the shortages for Auro-Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02452855), Sandoz Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02310333), Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02354748), Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02385945) and Teva-Venlafaxine XR 150 mg Extended-Release Capsule (DIN 02275058) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 8, 2020**.

VENLAFAXINE HCL

150 MG EXTENDED-RELEASE CAPSULE

00002331705	APO-VENLAFAXINE XR	APX	\$ 0.1927
00002452855	AURO-VENLAFAXINE XR	AUR	\$ 0.1927
00002278561	PMS-VENLAFAXINE XR	PMS	\$ 0.1927
00002380099	RAN-VENLAFAXINE XR	RAN	\$ 0.1927
00002310333	SANDOZ VENLAFAXINE XR	SDZ	\$ 0.1927
00002275058	TEVA-VENLAFAXINE XR	TEV	\$ 0.1927
00002354748	VENLAFAXINE XR	SNS	\$ 0.1927
00002385945	VENLAFAXINE XR	SIV	\$ 0.1927
00002237282	EFFEXOR XR	PFI	\$ 2.1124

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.828 2019/12

